NIKKEI 225
38,202.37 -632.73 (-1.63%) HANG SENG
18,313.86 -165.51 (-0.90%) CRUDE OIL
79.20 +0.21 (+0.27%) GOLD FUTURES
2,316.60 -5.70 (-0.25%) DOW
39,056.39 +172.13 (+0.44%) Bitcoin GBP
49,140.01 -1,209.95 (-2.40%)
IN8bio, Inc. (INAB)
After hours:
| Previous close | 1.0100 |
| Open | 1.0001 |
| Bid | 0.9774 x 100 |
| Ask | 1.0300 x 100 |
| Day's range | 1.0000 - 1.0299 |
| 52-week range | 0.6500 - 3.4800 |
| Volume | |
| Avg. volume | 345,740 |
| Market cap | 44.46M |
| Beta (5Y monthly) | -0.01 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.0000 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 7.90 |
GlobeNewswireIN8bio Doses First Patient in Phase 2 Clinical Trial of INB-400 in Newly Diagnosed Glioblastoma
NEW YORK, April 30, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company advancing innovative gamma-delta T cell therapies, announced today that the first patient in its Phase 2 clinical trial evaluating INB-400 in patients with newly diagnosed glioblastoma multiforme (GBM) has been successfully dosed at the Cleveland Clinic in Ohio. INB-400 is the Company’s first autologous gamma-delta T cell therapy product candidate genetically engineered to survive
- GlobeNewswire
IN8bio Announces Oral Presentation at the Upcoming American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting
NEW YORK, April 24, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced an oral presentation at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting, taking place May 7 – 11, 2024, in Baltimore, MD and virtually. Details of the oral presentation are as follows: Title: Healthy Donor vs Patient Manufactured Autologous Deltex DRI Product; Immunophenotyping Gene Expressi
- GlobeNewswire
IN8bio to Present at Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference
NEW YORK, April 16, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced that William Ho, CEO and Co-founder, will present at the Noble Capital Markets’ Emerging Growth Virtual Healthcare Equity Conference on Thursday, April 18th at 12:30pm ET. The formal presentation will feature a fireside style Q&A session with questions welcome from the live virtual audience. Attendees interested in
